<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424423</url>
  </required_header>
  <id_info>
    <org_study_id>112988</org_study_id>
    <nct_id>NCT01424423</nct_id>
  </id_info>
  <brief_title>NOGO-A in Multiple Sclerosis FTIH</brief_title>
  <official_title>A Randomized, Single-blind (Investigator and Subject), Placebo-controlled, Single Ascending Dose Study Exploring the Preliminary Safety, Tolerability, and Pharmacokinetics of GSK1223249 Administered by Intravenous (IV) Infusion to Subjects With Relapsing Forms of Multiple Sclerosis, Not on Disease Modifying Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The drug being tested in this study is GSK1223249. The drug works by inhibiting a protein&#xD;
      that prevents nerve growth.&#xD;
&#xD;
      The trial is expected to involve approximately 36 patients. The study objective is to&#xD;
      investigate the tolerability, safety and the way the body handles GSK1223249 after a range of&#xD;
      single doses in patients with Multiple Sclerosis (MS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I study of GSK1223249. The study design is randomized, placebo-controlled,&#xD;
      double-blind, sequential dose escalation, single dose administration. Approximately 36&#xD;
      patients with relapsing forms of Multiple Sclerosis (having had at least two relapses over&#xD;
      the previous 24 months, OR at least one relapse within the last 12 months, OR having had at&#xD;
      least one documented gadolinium-enhancing lesion on brain magnetic resonance imaging (MRI)&#xD;
      within 12 months prior to Screening) will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">February 11, 2010</start_date>
  <completion_date type="Actual">August 26, 2010</completion_date>
  <primary_completion_date type="Actual">August 26, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The preliminary safety and tolerability of single doses of GSK1223249</measure>
    <time_frame>screening, baseline (pre-dose) and up to 84 days post dose</time_frame>
    <description>changes in Vital signs, Electocardiogram, safety laboratory samples, adverse event (AE), neurological examination and MS relapses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single dose pharmacokinetics.</measure>
    <time_frame>screening, baseline (pre-dose) and up to 84 days post dose</time_frame>
    <description>(AUC(0-∞)</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Subjects receiving GSK1223249 in cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive intravenous infusion of GSK1223249 with a starting dose of 0.02 milligrams per kilograms, followed by 0.2, 2, 10 and 30 milligrams per kilograms, administered by a programmable syringe pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving placebo in cohort 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving GSK1223249 in cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 0.2 milligrams per kilograms administered by a programmable syringe pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving placebo in cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving GSK1223249 in cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 2 milligrams per kilograms administered by a programmable syringe pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving placebo in cohort 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving GSK1223249 in cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 10 milligrams per kilograms administered by a programmable syringe pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving placebo in cohort 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving GSK1223249 in cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 30 milligrams per kilograms administered by a programmable syringe pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving placebo in cohort 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Subjects receiving placebo in cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving placebo in cohort 2</arm_group_label>
    <arm_group_label>Subjects receiving placebo in cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving placebo in cohort 4</arm_group_label>
    <arm_group_label>Subjects receiving placebo in cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1223249</intervention_name>
    <description>I.V. Infusion</description>
    <arm_group_label>Subjects receiving GSK1223249 in cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving GSK1223249 in cohort 2</arm_group_label>
    <arm_group_label>Subjects receiving GSK1223249 in cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving GSK1223249 in cohort 4</arm_group_label>
    <arm_group_label>Subjects receiving GSK1223249 in cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suitable as determined by the Principal Investigator, based on his/her overall&#xD;
             evaluation. A patient with a clinical abnormality or laboratory parameters outside the&#xD;
             reference range for the population being studied may be included only if the&#xD;
             Investigator and the GSK Medical Monitor agree that the finding is unlikely to&#xD;
             introduce additional risk factors and will not interfere with the study procedures.&#xD;
&#xD;
          -  Diagnosed with a relapsing form of MS defined as either&#xD;
&#xD;
          -  Relapsing Remitting MS according to revised McDonald Criteria [McDonald, 2001; Polman,&#xD;
             2005] plus any one of the following:&#xD;
&#xD;
        Occurrence of at least one relapse in the previous 12 months OR at least 2 relapses in the&#xD;
        previous 24 months OR at least one documented Gd-enhancing lesion by magnetic resonance&#xD;
        imaging (MRI) within 12 months prior to screening.&#xD;
&#xD;
        OR&#xD;
&#xD;
        -Secondary Progressive MS, plus any one of the following: Occurrence of at least one&#xD;
        relapse in the previous 12 months OR at least 2 relapses in the previous 24 months OR at&#xD;
        least one documented Gd-enhancing lesion by magnetic resonance imaging (MRI) within 12&#xD;
        months prior to screening.&#xD;
&#xD;
          -  Expanded Disability Status Scale (EDSS) score ≤5.5&#xD;
&#xD;
          -  Male or female between 18 and 55 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal baseline blood tests&#xD;
&#xD;
          -  Treatment with interferon-beta-1b (Betaferon), interferon-beta-1a (Rebif or Avonex),&#xD;
             or glatiramer acetate (Copaxone) within 90 days of dosing.&#xD;
&#xD;
          -  Treatment with methylprednisolone or any other systemic steroids within 60 days of&#xD;
             dosing.&#xD;
&#xD;
          -  Treatment within the past 12 months or currently with any of the following agents:&#xD;
             cyclosporine, azathioprine, methotrexate, cladribine, natalizumab (Tysabri®) or other&#xD;
             monoclonal antibodies, murine protein, T-cell vaccination, plasmapheresis, IVI gG,&#xD;
             ,stem cell transplantation.&#xD;
&#xD;
          -  History of intolerance to acetominophen, ibuprofen, naproxen or any other&#xD;
             non-steroidal anti-inflammatory agent which would preclude use of at least one of&#xD;
             these during the study.&#xD;
&#xD;
          -  Previous history of anaphylaxis, severe allergic reaction, or hypersensitivity to&#xD;
             albumin or a protein-based therapeutic, including natalizumab (Tysabri) or any other&#xD;
             monoclonal antibody. History of hypersensitivity to any of the components of the&#xD;
             formulation.&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result.&#xD;
&#xD;
          -  Patients with evidence of dementia or psychiatric illness which, in the Investigator's&#xD;
             opinion, is likely to prevent them from a full understanding of and/or compliance with&#xD;
             the study requirements and procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>VIC 3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2011</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>GSK1223249</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Single dose escalation</keyword>
  <keyword>anti-GSK1223249 antibodies</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

